Prelude Therapeutics Inc (PRLD) Stock Price & Analysis
Prelude Therapeutics Inc (PRLD) rose 2.60% to USD 3.94 as of June 10, 2026 at 02:23 UTC, according to Nexqual real-time market data.
PRLD last closed at USD 3.84; the session ranged USD 3.76–4.02 on volume of 235,360 shares. Market capitalization is $313.80M, with a 52-week range of USD 0.75–5.54 (NMS). Source: Nexqual, June 10, 2026 at 02:23 UTC.
Key Statistics (as of June 10, 2026 at 02:23 UTC)
| Price | USD 3.94 |
|---|---|
| Change | ▲ 2.60% (up) |
| Previous Close | USD 3.84 |
| Open | USD 3.87 |
| Day Range | USD 3.76 – 4.02 |
| 52-Week Range | USD 0.75 – 5.54 |
| Volume | 235,360 shares |
| Market Cap | $313.80M |
| Exchange | NMS |
Technical Analysis (PRLD)
Nexqual's technical model rates PRLD "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:23 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 46.77 (neutral) |
| vs SMA50 | Below (USD 4.3) |
| MACD | -0.15 (negative) |
Analyst Ratings (PRLD)
Wall Street analysts rate PRLD "Strong Buy" based on 3 analysts, with a mean price target of USD 8 (range USD 6–10), per Nexqual as of June 10, 2026 at 02:23 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 8 |
| High Target | USD 10 |
| Low Target | USD 6 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (PRLD)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.24 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.13 vs est -0.27 ▲ beat |
| 2025-12-31 | USD -0.2 vs est -0.18 ▼ miss |
| 2025-09-30 | USD -0.26 vs est -0.36 ▲ beat |
| 2025-06-30 | USD -0.41 vs est -0.43 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
Financials & Fundamentals (PRLD)
| Total Revenue | $16.72M |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -309.54% |
| Profit Margin | +0.00% |
| ROE | -95.25% |
| Debt / Equity | 29.45 |
| Current Ratio | 2.03 |
| Total Cash | $81.55M |
| Total Debt | $17.72M |
| Free Cash Flow | $-17.93M |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
Financial Health Score (PRLD)
Nexqual rates Prelude Therapeutics Inc's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:23 UTC.
| Growth | Strong — Revenue +73% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $82M cash vs $18M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$18M, burning cash |
| Efficiency | Critical — ROE -95%, ROA -39.7% |
Ownership (PRLD)
| Insider Ownership | +13.80% |
|---|---|
| Institutional Ownership | +64.32% |
| Shares Outstanding | 64.92M |
| Float | 27.59M |
| Short % of Float | +6.73% |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
Leadership (PRLD)
Prelude Therapeutics Inc is led by Krishna Vaddi D.V.M. (age 59), Founder, CEO & Director, per Nexqual as of June 10, 2026 at 02:23 UTC.
| Founder, CEO & Director | Krishna Vaddi D.V.M. (age 59) |
|---|---|
| CFO, Chief Legal Officer & Corporate Secretary | Bryant David Lim (age 54) |
| Chief Scientific Officer | Peggy A. Scherle (age 63) |
| Senior Vice President of Technical Operations | Madhu Pudipeddi |
| Senior Vice President of Investor Relations | Robert A. Doody |
Major Backers & Investors (PRLD)
Notable institutional backers of Prelude Therapeutics Inc include Orbimed Advisors LLC., Baker Bros. Advisors, LP, Kynam Capital Management, LP, according to Nexqual as of June 10, 2026 at 02:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Orbimed Advisors LLC. | 20.83% |
| Baker Bros. Advisors, LP | 12.71% |
| Kynam Capital Management, LP | 2% |
| EcoR1 Capital, LLC | 1.19% |
| Two Sigma Investments, LP | 1.16% |
| Sphera Funds Management Ltd. | 0.7% |
| Acadian Asset Management. LLC | 0.64% |
| Millennium Management | 0.48% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.07% |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
From Prelude Therapeutics Inc's Latest SEC 10-K Filing (filed 2026-03-10)
Key Strengths & Strategy (as disclosed to the SEC)
- Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
- It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
- The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PMVP | PMV Pharmaceuticals, Inc. | USD 1.05 | ▼ 6.25% |
| FHTX | Foghorn Therapeutics Inc. | USD 3.87 | ▲ 3.75% |
| STTK | Shattuck Labs, Inc. | USD 4.27 | ▼ 6.77% |
| CCCC | C4 Therapeutics, Inc. | USD 3.58 | ▼ 7.01% |
| KYMR | Kymera Therapeutics, Inc. | USD 76.91 | ▲ 3.75% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:23 UTC. This page is informational and not investment advice.